Oramed Pharmaceuticals

ORMP · NASDAQ

$4.15+$0.09 (+2.22%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $4.06

ORMP analyst rating

This isn't available right now. Refresh to try again.

The case for and against

Updated Nov 27, 2024

Bull case

Oramed Pharmaceuticals Inc. has entered into a joint venture agreement with HTIT, which signifies a strategic collaboration aimed at commercializing its innovative oral drug delivery technology. This partnership not only enhances Oramed's financial resources but also allows potential revenue generation from a new product pipeline, including a topical treatment acquired from PeriTech Pharma Ltd. Moreover, the increased funding commitment from HTIT, raised from an initial $60 million, signifies robust investor confidence in Oramed's technology and market potential, contributing to an optimistic outlook for the company's financial future.

Bear case

Oramed Pharmaceuticals Inc. faces significant risks, including the potential for adverse results from future clinical trials and challenges in repositioning the company after the discontinuation of the ORMD-0801 program for Type 2 diabetes. The company's product pipeline has not yet demonstrated definitive clinical proof-of-concept efficacy, raising concerns about its ability to advance its therapeutic candidates effectively. Furthermore, negative regulatory actions and long-term dilution risks contribute to a negative outlook regarding the company's financial stability and growth prospects.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.